EVENTS & PRESENTATIONS

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study

June 3, 2017

Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma

April 2, 2017

Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer

November 29 – December 2, 2016

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors

May 29 – June 2, 2015

The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

April 18 – 22, 2015

Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer

March 2 – 4, 2015

Phase 1 Trial of Image-Guided Oncolysis by Clostridium Novyi-NT Spore Inoculation: Early Technical Insights

January 31, 2015

PUBLICATIONS

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

Abstract | Commentary

[(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prothetic joint infection.

Abstract

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.

Abstract

Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.

Abstract

Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent.

Abstract

MRI-Monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model.

Abstract

TNF-Alpha blockade is ineffective in animal models of established polycystic kidney disease.

Abstract

Novel anti-inflammatory effects of doxazosin in rodent models of inflammation.

Abstract

Possible therapeutic effect of trilostaine in rodent models of inflammation and nociception.

Abstract

Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.

Abstract

Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis.

Abstract

Novel anti-inflammatory effects of repaglinide in rodent models of inflammation.

Abstract

Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.

Abstract

In vivo effects of immunomodulators in a murine model of Fluorouracil-induced mucositis.

Abstract

PRESS RELEASES

BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting

May 26, 2017

Bacterial biosurgery shows promise for reducing the size of inoperable tumors

August 13, 2014

MEDIA

The media relations team at the BioMed Valley Discoveries works with local, regional, national, and international media organizations to provide reporters with accurate and timely information about our latest discoveries.

Members of the news media may email inquiries to mediacontact@biomed-valley.com or contact Kimberly Bland, PhD, at 816-392-8428.

If you are not a member of the news media or do not have a media-related question, please use the contact form.